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Abstract
Background: Intravascular leukocyte recruitment in most vertebrate tissues is restricted to postcapillary and
collecting venules, whereas capillaries and arterioles usually support little or no leukocyte adhesion. This segmental
restriction is thought to be mediated by endothelial, rather than hemodynamic, differences. The underlying
mechanisms are largely unknown, in part because effective tools to distinguish, isolate, and analyze venular
endothelial cells (V-ECs) and non-venular endothelial cells (NV-ECs) have been unavailable. We hypothesized that
the atypical chemokine receptor DARC (Duffy Antigen Receptor for Chemokines, a.k.a. ACKR1 or CD234) may
distinguish V-ECs versus NV-ECs in mice.
Methods: We generated a rat-anti-mouse monoclonal antibody (MAb) that specifically recognizes the erythroid and
endothelial forms of native, surface-expressed DARC. Using this reagent, we characterized DARC expression and
distribution in the microvasculature of murine tissues.
Results: DARC was exquisitely restricted to post-capillary and small collecting venules and completely absent from
arteries, arterioles, capillaries, veins, and most lymphatics in every tissue analyzed. Accordingly, intravital microscopy
showed that adhesive leukocyte-endothelial interactions were restricted to DARC+ venules. DARC was detectable
over the entire circumference of V-ECs, but was more concentrated at cell-cell junctions. Analysis of single-cell
suspensions suggested that the frequency of V-ECs among the total microvascular EC pool varies considerably
between different tissues.
Conclusions: Immunostaining of endothelial DARC allows the identification and isolation of intact V-ECs from
multiple murine tissues. This strategy may be useful to dissect the mechanisms underlying segmental microvascular
specialization in healthy and diseased tissues and to characterize the role of EC subsets in tissue-homeostasis,
immune surveillance, infection, inflammation, and malignancies.
Keywords: Monoclonal antibody, Microvascular endothelium, Leukocyte adhesion, DARC/ACKR1, Chemokines
Background
The peripheral circulatory system is segmentally orga-
nized into sparse arteries and arterioles that feed a dense
capillary network drained by postcapillary venules
(PCVs) that merge into collecting venules (CVs) and
veins. In most tissues, each vascular segment is
dedicated to a specific task – arteries and arterioles
regulate blood flow, gas and nutrient exchange occurs in
capillaries, and leukocyte adhesion and emigration is re-
stricted to PCVs and CVs [1].
Although the expression of some gene products by
endothelial cells (ECs) is regulated by hydrodynamic
shear stress [2], there is evidence that the specialized
function of venules in leukocyte adhesion is due to seg-
mentally distinct endothelial programming, rather than
hemodynamic differences [3]. Indeed, the specification
of microvascular segments during embryogenesis is
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established before the initiation of blood flow [4]. Stud-
ies employing intravital microscopy (IVM) have demon-
strated that the initial attachment and arrest of free
flowing leukocytes to the microvascular wall in most tis-
sues (except in lung, liver, and spleen) is a feature of
PCVs and CVs, whereas capillaries and arterioles usually
do not support leukocyte trafficking [5]. This
specialization of venular endothelium is found in verte-
brates ranging from agnathans to mammals [1, 6] and in
both adults and fetuses [7].
Leukocyte recruitment from blood to tissues follows a
well-established paradigm, the multi-step adhesion cas-
cade, which distinguishes at least three consecutive dy-
namic interactions, namely leukocyte tethering and
rolling, chemoattractant-induced activation, and integrin-
mediated firm arrest [8]. Adherent cells then undergo
intraluminal crawling followed by transmigration across
the endothelial barrier [9]. These in vivo observations are
consistent with reports on preferential venular expression
of various adhesion molecules, the molecular nature and
composition of which vary among different microvascular
beds [8]. However, the underlying differentiation program
that enables venular endothelial cells (V-ECs) to express
leukocyte traffic molecules, but prohibits non-venular
endothelial cells (NV-ECs) in capillaries and arterioles
from doing so is unknown.
A handful of markers have been suggested to distin-
guish V-ECs from NV-ECs. One candidate is the atypical
chemokine receptor DARC (Duffy Antigen Receptor for
Chemokines, a.k.a. CD234, Atypical Chemokine
Receptor-1 or ACKR1), which binds several pro-
inflammatory CC and CXC chemokines [10, 11]. DARC
regulates the activity of these chemokines by transcytos-
ing them across the endothelial barrier [12]. DARC has
been shown to delineate V-ECs in human kidney [13]
and spleen [14] and high endothelial venules (HEVs) in
murine lymph nodes (LNs) [15]. Recently, endothelial
DARC expression was reported in experimental athero-
sclerosis and encephalitis on sections of the aorta [16]
and in brain microvasculature [17], respectively.
Aside from ECs, DARC is also expressed in the eryth-
roid lineage. Indeed, DARC was first described as a
blood group antigen [18, 19] and its role on red blood
cells (RBCs) has been studied extensively [11]. Erythroid
DARC modulates the bioavailability of serum chemo-
kines and serves as an entry receptor for P. vivax and P.
knowlesi, enabling infection of RBCs by these pathogens
[20, 21]. Immunostaining of human tissues has identified
DARC on a few non-vascular cell types, such as Purkinje
cells [22] and renal epithelial cells [23]. More recently,
using a commercial polyclonal Ab against murine
DARC, DARC expression was reported on bone marrow
(BM) macrophages [24]. The same study reported that
DARC was essentially undetectable on microvascular
endothelium from a variety of mouse tissues, which ap-
peared to be in contrast to previous observations in
humans. Thus, it is currently unclear whether and to
what extent DARC can serve as a reliable marker of V-
ECs in mice. Indeed, presumably due to a lack of suit-
able reagents, a systematic analysis of microvascular
DARC expression in murine tissues has not been per-
formed so far.
Here, using a newly generated monoclonal Ab (MAb)
against mouse DARC, we have explored DARC as an
endothelial surface marker in a variety of murine tissues
and assessed the utility of this research tool for flow cy-
tometry, immunofluorescence microscopy, IVM, and
Western blot analysis. We show that anti-DARC MAb
can be used to identify and isolate ECs from PCVs and
CVs in vitro and in vivo and that DARC expression is
uniformly expressed and highly restricted to venules in
multiple organs. Using flow cytometry, we determined
that the relative abundance of V-ECs varies considerably
between different tissues, possibly reflecting organ-




C57BL/6 (catalog number 027) and BALB/c mice (RRID:
IMSR_JAX:000651, catalog number 000651), 6–12 weeks
old, were purchased from Charles River or Jackson La-
boratories. DARC–/– mice [25] were bred at the Univer-
sity of York and used as tissue donors. Apoe−/− mice
[26] were obtained from Jackson Laboratories (RRID:
IMSR_JAX:002052, catalog number 002052). BM chi-
meras were generated by irradiating C57BL/6 mice (2 ×
650 Rad) followed by intravenous (IV) injection of
unfractionated DARC–/– BM mononuclear cells and a
rest period of more than 12 weeks before use. Mice were
housed under specific pathogen-free conditions in ac-
cordance with NIH guidelines. Experimental protocols
were approved by the Institutional Animal Care and Use
Committee at Harvard Medical School.
Construction of expression plasmids
The entire open reading frame of murine DARC was
PCR amplified from brain cDNA and subcloned into
pCR4Blunt-TOPO (Invitrogen Life Technologies). A
DARC-eGFP fusion construct was created by overlap ex-
tension PCR [27]. BamHI and ECORI were used to in-
sert DARC-eGFP into pcDNA3.1 expression vector
(Invitrogen). Primer sequences are provided in Table 1.
Monoclonal anti-mouse DARC antibody
The rat cell line PC-12 (ATCC) was grown in F-12 K
media (Gibco) with 2.5% fetal bovine serum (FBS) and
15% horse serum. The human embryonic kidney cell line
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HEK-293 was grown in DMEM (Corning) with 10% FBS.
Both cell lines were stably transfected in 10-cm Petri
dishes with 2 μg of plasmid using Lipofectamin 2000
(Invitrogen) following the manufacturer’s protocol. PC-
12 cells were transfected with DARC-eGFP fusion pro-
tein and linker LG (named DARC-eGFP1) and HEK-293
were transfected with DARC-eGFP fusion protein and
linker GGGGSAAA (named DARC-eGFP3). The anti-
biotic G418 (GIBCO) was added at a final concentration
of 400 μg/mL 24 h after transfection. The selection
medium was renewed every 3–4 days. Stable transfec-
tants were further selected by cell sorting based on GFP
expression. PC-12 DARC-eGFP transfectants were con-
ditioned overnight with media supplemented with
10 mM sodium butyrate solution to boost transgene ex-
pression before immunization. Adult rats were immu-
nized four times at 2-week intervals with 5 × 106 sodium
butyrate-conditioned DARC-eGFP PC-12 cells. For the
first immunization, transfectants were suspended in
complete Freund’s adjuvant and injected by sub-
cutaneous (s.c.) and intra-peritonal (i.p.) routes; the first
booster injection of transfectants suspended in incom-
plete Freund’s adjuvant was performed by i.p. and subse-
quent injections were performed without adjuvants by
the i.p. route. Immunization and fusion of hybridomas
were performed by Abpro Biotechnology company
under a service contract. Cloning and sub-cloning of the
hybridomas was performed in the Dana Farber Mono-
clonal Antibody Core, Boston. Immune sera were
screened by flow cytometry for reactivity with DARC
ectodomains using HEK-293 cells expressing DARC-
eGFP fusion protein and RBCs from wildtype (WT) or
DARC–/– mice. Following splenocyte fusion, twelve 96-
well plates were screened by flow cytometry. Two wells
showed reactivity against mouse DARC. One clone pro-
ducing an anti-mouse DARC MAb was isolated, ex-
panded, and subcloned; the MAb was determined to be
a rat IgG2a,k isotype. See Additional file 1: Figure S1.
Antibodies for immunofluorescence staining
Anti-mouse DARC MAb was conjugated to Alexa Fluor
dyes 488, 546, or 647. Anti-Lyve-1 (clone ALY7; eBios-
ciences) was conjugated to Pacific blue using a commer-
cial kit (Molecular Probes). DAPI (Invitrogen) was used
to stain nuclei in immunohistochemistry. UEA-1 lectin
(Vector Labs) against mTECs was conjugated to Alexa
Fluor 647. Insulin was detected using GP-anti-bovine in-
sulin serum (Linco Research Inc.). See complete list of
antibodies in Table 2.
Confocal microscopy and image analysis
For whole-mount staining, omentum, ear, cremaster
muscle, and bladder were harvested from young adult
donor mice and immediately fixed in phosphate-
buffered 1% paraformaldehyde/1.5% L-lysine/0.2% so-
dium periodate (PLP) sodium phosphate dibasic (0.1 M
Na2HPO4) solution, pH = 7, overnight at 4 °C. Conjunc-
tivae were fixed in acetone for 10 min at room
temperature. For frozen sections, tissues were fixed in
PLP overnight (4 °C) followed by incubation in 30% su-
crose in phosphate-buffered saline (PBS). Samples were
snap-frozen in Tissue Freezing Medium (Triangle Bio-
medical Sciences) and stored at –80 °C. Thin sections
(30 μm) were prepared on a cryostat, mounted on
Superfrost Plus slides (VWR), and stained with fluores-
cent antibodies in a humidified chamber after FcR block-
ade with 2.4G2 antibody. 2.4G2 mAb blocks non-
antigen-specific binding of immunoglobulins to the
FcγIII and FcγII, and possibly FcγI, receptors. Tissues
were stained (overnight, 4 °C) in blocking buffer and
washed (see list of buffers in Table 3). Whole-mount
preparations were mounted between two coverslips
Table 1 Primers
Primers to create DARC-eGFP fusion protein
DARC Fwd 5′- GCC ACC ATG GGG AAC TGT CT
DARC Rvs 5′-GGA CTT GCC TGC AAG GGC AT
BamH1-
DARC Fwd




5′- CCC TTG CTC ACC ATC TCG AGG GAC TTG CCT
GCA AGG GCA TC
DARC-linker3
Rvs
5′- CGC CGC GCT GCC GCC GCC GCC GGA CTT GCC
TGC AAG GGC ATC
GFP-linker1
Fwd
5′- TTG CAG GCA AGT CCC TCG AGA TGG TGA GCA
AGG GCG AGG AG
GFP-linker3
Fwd
5′- GGC GGC GGC AGC GCG GCG GCG ATG GTG AGC
AAG GGC GAG GAG
GFP-ECORI
Rvs















Sele Fwd TGAACTGAAGGGATCAAGAAGACT From McEver et al.
[70]
Sele Rvs GCCGAGGGACATCATCACAT
Chst4 Fwd TGCCCCACCTCCAAACAT From Ruddle et al.
[71]
Chst4 Rvs GACCAACGCCACGCCTGAGA
Fut7 Fwd GGACCTCCTCGGGCCACCTACG From Ruddle et al.
[71]
Fut7 Rvs CGCCAAGCAAAGAAGCCACGATAA
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(VWR) with Genteal (Acori); frozen sections were
mounted in FluorSave reagent (Calbiochem) and
stored at 4 °C.
Two whole mounts of fresh murine omentum were
prepared and stained for CD31 and DARC, as described
above, and z-stacks of confocal micrographs were ac-
quired (10 or 15 images at 2.9 μm vertical step intervals).
Fluorescent images were used for 3D rendering using
Imaris software. Supporting data values for all surface
areas are included in Additional file 2.
Confocal images were acquired on an Olympus Fluo-
view BX50WI inverted microscope with × 10/0.4, ×20/
0.5, and × 40/1.3 objectives. Image stacks for three-
dimensional reconstructions were acquired at 1–4.5 μm
Z-intervals. Image analysis was performed using Volocity
(Improvision) or Imaris (Bitplane) software.
Preparation of aorta
To induce atherosclerosis, Apoe–/– mice were fed a
Western diet (Harlan Teklad) for 12 weeks prior to ana-
lysis [28]. Aortic root tissue was frozen in OCT and 5-
μm thick sections were cut with a cryostat. Sections
were fixed in isopropanol for 10 min at 4 °C and blocked
with PBS + 10% goat serum + 0.5% BSA. Staining was
performed overnight at 4 °C with AF546-anti-DARC
antibody + APC-anti-CD31 (MEC 13.3). Samples were
fixed in 4% PFA for 10 min, nuclei were stained with
Yoyo-1, and sections were mounted using Prolong Gold
Table 2 Antibodies for immunofluorescence staining
Label Antibody Clone Company Catalog
number
RRID number







anti-PNAd Clone MECA-79 eBioscience 53-6036 AB_10804391
anti-MAdCAM-1 Clone MECA-367 Biolegend 120707 AB_493399
Anti-LYVE1 Clone ALY7 eBioscience 53-0443 AB_1633415
Rat IgG2a, κ isotype control Biolegend 400525 AB_389320
Rat IgM, κ isotype control Biolegend 400811 AB_1659271
PE conjugated anti-CD31 Clone 390 Biolegend 102408 AB_312903
Anti-ICAM-1 3E2 BD Pharmingen 553253 AB_394735
Armenian Hamster IgG Isotype control Biolegend 400908 AB_326594
PE-Cy7 conjugated anti-gp38 Clone 8.1.1 Biolegend 127411 AB_10613294
anti-TER-119 Clone TER-119 Biolegend 116222 AB_2281408
Alexa Fluor 647 conjugated Anti-DARC Clone 6B7 Generated in-house
rat IgG2a,k isotype control Biolegend 400526 AB_389342
APC-Cy7 conjugated anti-TER-119 Clone TER-119 Biolegend 116223 AB_2137788
Anti-CD45.2 Clone 104 Biolegend 109824 AB_830789
anti-CD11b Clone M1/70 Biolegend 101226 AB_10784810
Pacific blue conjugated anti-CD45.2 Clone 104 Biolegend 109820 AB_492872
Anti-CD45 Clone 30-F11 Biolegend 103126 AB_493535
Anti-CD31 Clone 390 102422 AB_10612926
Brilliant violet 510 conjugated Anti-CD45 Clone 30-F11 Biolegend 103138 AB_2563061
Alexa Fluor 546 conjugated Anti-DARC Clone 6B7 Generated in-house
Alexa Fluor 605 conjugated Anti-CD31 Clone 390 Biolegend 102427 AB_2563982
Anti-CD45 Clone 30-F11 103139 AB_2562341












HBSS (Corning) with 2% FBS (Gemini), 10 mM HEPES
(Corning) and 2 mM CaCl2 (Sigma)
FACS buffer PBS (Lonza) with 5% FCS (Invitrogen-Gibco) and 5 mM
EDTA (Boston BioProducts)
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reagent. Images of the vasa vasorum of aorta were ac-
quired on a Leica SP5 microscope.
Tissue digestion
Lymph node and brain tissues were digested with
2.5 mg/mL Collagenase D (Roche), 50 μg/mL DNAse I
(Roche), and 0.4× protease inhibitor (Roche) in digestion
buffer at 37 °C. Digestion of LNs was adapted from
Fletcher et al. [29], such that tissues were digested for
20 min without protease inhibitor followed by three 10-
min incubations with protease inhibitor. Brain tissues
were digested for 15–20 min at 37 °C. Enrichment of
ECs was performed by centrifugation at 5000 g for
30 min at 4 °C in a dextran solution (17% dextran
(Sigma, catalog number 31392)/20 mM HEPES). Skin,
colon, and small intestine tissues were digested with
2.5 mg/mL Collagenase D (Roche), 50 μg/mL DNAse I
(Roche), and 1× protease inhibitor (Roche) in digestion
buffer for 30 min at 37 °C on a rotisserie wheel. Colon
and small intestine were washed with 5% FBS and
25 mM HEPES, followed by 2 mM EDTA and 25 mM
HEPES, and finally 10% FBS, 5 mM EDTA, and 15 mM
HEPES prior to enzymatic digestion to remove epithelial
cells. Pancreatic and adipose tissues were digested with
1.25 mg/mL Collagenase D (Roche), 50 μg/mL DNAse I
(Roche), and 1× protease inhibitor (Roche) in digestion
buffer for 30 min at 37 °C on a rotisserie wheel. Cells
were resuspended in FACS buffer (PBS (Lonza), 5% FBS
(Invitrogen-Gibco), 5 mM EDTA (Boston BioProducts))
for analysis.
Flow cytometry
Single-cell suspensions were immunostained, washed,
and resuspended in FACS buffer containing 7-AAD via-
bility stain (BioLegend) for immediate acquisition using
a BD FACS CANTO, BD LSRII (BD Biosciences), or
CytoFlex (Beckman Coulter) and analyzed using FlowJo
software (Treestar).
RT-qPCR
EC subsets were FACS-sorted using an Aria I cell sorter
(BD Biosciences) and collected in Trizol (Ambion). RNA
extraction was performed prior to cDNA synthesis using
the iScript kit (BioRad). qPCR was performed on a
LightCycler 480 II (Roche) using SybGreen Quantifast
kit (Qiagen). Relative gene expression was calculated
using the ΔCT method. See list of primers in Table 1.
Intravital microscopy (IVM)
IVM of subiliac lymph node, skin, BM, and cremaster
muscle was performed as previously described [5, 30–
32] using an IV-500 intravital microscope (Mikron In-
struments), equipped with a Rapp OptoElectronic SP-20
xenon flash lamp system and QImaging Rolera-MGi
EMCCD camera.
Western blot analysis
Protein extracts were loaded on a 4–12% Tris-Glycine
precast gel (Invitrogen). Precision Plus protein Kaleido-
scope standards (Bio-Rad, catalog number 161-0375)
were used as controls for molecular weight. Heat-
denaturation of protein samples was performed. Mem-
branes were incubated with anti-mouse DARC MAb and
revealed using HRP-linked anti-rat antibody (Cell Signal-
ing, RRID AB_10694715, catalog number 7077S). Anti-
β-actin antibody (Sigma, RRID AB_476743, catalog
number A5316) was used for loading control. Immuno-
reactive proteins were detected with Pierce ECL Western
Blotting Substrate (Thermo Scientific).
Chemokine binding assay
Chemokine binding to RBCs was assessed as previously
described [33], with slight modifications. RBCs were in-
cubated with increasing chemokine concentrations (10–
10–10–5 M or 10–11–10–7 M of CXCL8 or mCXCL1, re-
spectively), with either anti-human DARC MAb Fy6 (gift
from Dr. M. Uchikawa, Japanese Red Cross) or anti-
mouse DARC MAb. Mean fluorescence of MAb staining
was analyzed by FACS. IC50 was calculated using Graph-
Pad Prism software.
Statistical analysis
Results are expressed as means ± SEM. All statistical
analyses were performed in Prism (GraphPad Software)
or Excel Software. Means between two groups were
compared by two-tailed t-test. Means between three or
more groups were compared by one-way or two-way
ANOVA with Tukey’s or Dunnett’s Multiple Comparison
Test. The numbers of replicates or animals are indicated
in figure legends.
Results
Validation of anti-mouse DARC mAb specificity
After immunization of a rat with DARC-eGFP trans-
fected PC-12 cells, hybridoma lines were generated and
supernatants screened by FACS. One hybridoma super-
natant stained HEK-293 cells transfected with DARC or
DARC-eGFP (Fig. 1a), as well as RBCs from C57BL/6
WT mice (Fig. 1b), but not untransfected HEK-293 cells
or DARC–/– RBCs. This hybridoma was subcloned and
determined to produce a single MAb of IgG2a,k isotype.
Both supernatant and purified IgG recognized DARC
protein in lysates of DARC or DARC-eGFP transfected
HEK-293 cells by Western blot (Fig. 1c). No signal was
detected with the parental untransfected HEK-293 line.
Robust immunoreactivity was also observed with TER-
119+ RBCs from Balb/c mice. The MAb did not cross-























































































































Ctrl DARC Ctrl 
Fig. 1 Validation of anti-mouse DARC MAb reactivity. a Representative flow cytometry histograms of control HEK-293 cells (none) and HEK-293
cells transfected with DARC or DARC-eGFP fusion protein stained with anti-mouse DARC MAb (n = 3 experiments). b Flow cytometry analysis of
anti-mouse DARC MAb reactivity with RBCs. Peripheral blood was harvested from wildtype (WT) and DARC–/– mice and stained with a MAb
against the RBC marker TER-119 and anti-mouse DARC MAb (black line) or isotype control MAb (grey) (n > 8 experiments). c Western blot analysis
of anti-mouse DARC MAb reactivity with protein lysates from untransfected HEK-293 cells and HEK-293 cells stably transfected with DARC or
DARC-eGFP fusion protein. b-Actin is shown as loading control (n = 4 experiments). d Representative confocal fluorescent micrographs of frozen
sections of peripheral lymph nodes from DARC WT and DARC–/– mice stained with MAbs against CD31 (green), peripheral node addressin (PNAd;
blue), and DARC or isotype control (red). 20× objective, scale bars = 200 μm (n = 3 experiments)
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react with RBCs from other species, including rat and
human (Additional file 3: Figure S2). Confocal micros-
copy of peripheral lymph node (PLN) sections revealed
that anti-DARC MAb colocalized with MAb MECA-79,
which specifically delineates peripheral node addressin
(PNAd), a marker of HEVs [34]. No microvascular re-
activity was detected in DARC–/– PLNs (Fig. 1d).
To assess whether the anti-DARC MAb is sensitive to
DARC occupancy with chemokines, we assessed staining
of WT RBCs in the presence of CXCL1 or CXCL8. Nei-
ther chemokine affected binding of the anti-mouse
MAb, whereas both blocked staining of human RBCs
with anti-human DARC MAb Fy6 (Additional file 3: Fig-
ure S2C), consistent with previous studies [35, 36]. Thus,
although the exact epitope recognized by our anti-
mouse DARC MAb was not identified, it is unlikely to
overlap with the chemokine binding region(s) of DARC.
DARC expression is restricted to V-ECs
Confocal micrographs of whole mounts of murine adi-
pose tissue and skin showed that DARC immunoreactiv-
ity was exclusively biased toward venules (Fig. 2a). No
signal was detected in either arterioles or the vast major-
ity of capillaries. On V-ECs, DARC appeared to be
enriched at intercellular junctions between adjacent ECs.
To quantify the frequency of DARC+ and DARC–
microvessels, we categorized CD31+ microvascular seg-
ments based on their morphology and caliber in whole
mounts of omentum. Virtually all PCVs and CVs were
DARC+, whereas arterioles and downstream capillaries
were consistently DARC–. The transition from DARC–
to DARC+ ECs occurred either at the point where capil-
laries merged to form a PCV or slightly upstream in
pre-venular capillaries (Fig. 2b and Additional file 4: Fig-
ure S3). DARC staining in venules was generally uniform
and without obvious gaps in immunoreactivity, suggest-
ing that essentially all V-ECs express DARC. Analogous
distribution patterns were detected in multiple tissues,
including cremaster muscle, bladder, conjunctiva, brain,
Peyer’s patches, mesenteric LNs (MLNs), thymus, pan-
creas, small intestine, and colon (Fig. 3). DARC was un-
detectable in large veins or arteries, including the lumen
of the aorta (Additional file 5: Figure S4 and Additional
file 6: Figure S5A). However, DARC was readily detected
in vasa vasorum around the aorta of WT mice, and ex-
pression in these vessels appeared to be further en-
hanced in atherosclerotic aortas in Apoe–/– mice
(Additional file 6: Figure S5B).
Flow cytometric analysis of DARC expression on
microvascular EC subsets
To more precisely define the frequency and distribution
of DARC+ and DARC– ECs, we stained single-cell
suspensions from normal tissues with fluorophore-
conjugated anti-mouse DARC MAb combined with
markers of leukocytes (CD45), myeloid phagocytes
(CD11b), RBCs (TER-119), the pan-endothelial marker
CD31, and gp38, which detects lymphatic ECs (LECs).
This staining strategy combined with gating on charac-
teristic forward and side light scatter profiles allowed
simultaneous discrimination of V-EC (CD45–TER-119–
CD11b–gp38–CD31+DARC+), NV-ECs (CD45–TER-119–
CD11b–gp38–CD31+ DARC–) and LECs (CD45–TER-
119–CD11b–gp38+CD31+) in multiple tissues (Fig. 4a).
To obtain single-cell suspensions, a number of mouse
tissues, including skin, LNs, adipose tissue, colon, small
intestine, brain, and pancreas, were mechanically disso-
ciated and incubated with a mixture of proteases. Pilot
experiments revealed that the epitope recognized by the
anti-mouse DARC MAb on both ECs and RBCs was
susceptible to degradation by neutral proteases (Add-
itional file 7: Figure S6). We developed, for each tissue,
specific digestion protocols that could reliably preserve
DARC staining on both RBCs and V-ECs using distinct
combinations of protease cocktails and protease inhibi-
tors (Fig. 4b).
Using this approach, we assessed the frequency of V-
ECs among total blood ECs (BECs) in each tissue sample
by flow cytometry (Fig. 4c). The recovery of DARC+ V-
ECs relative to the total yield of BECs was similar in skin
and LNs while adipose tissue, colon, small intestine,
brain, and pancreas yielded a lower frequency of DARC+
V-ECs among BECs. Several factors could potentially
contribute to the observed differences between tissues in
apparent V-EC frequency, as detected by flow cytometry.
(1) V-ECs in some tissues may contain a variably sized
population that does not express DARC. However, given
the uniformity of venular DARC staining in whole
mount preparations, we consider this unlikely. (2) Prote-
ases used to prepare single-cell suspensions for FACS
analysis may have destroyed DARC epitopes on a frac-
tion of V-ECs in some tissues, which could potentially
lead to an underestimation of the DARC+ EC fraction in
those tissues. However, our tissue digestion protocols
were devised to mitigate this effect as far as possible,
and we monitored Ter-119+ RBCs in tissue preparations
to ensure conservation of DARC epitopes. (3) The rela-
tive rate of recovery of V-EC versus NV-EC may differ
between tissues. (4) The observed measurements may
reflect true differences in V-EC abundance between
tissues.
To independently address the latter two (non-exclu-
sive) points, we conducted a digital 3D analysis of a
whole mount staining of murine omentum by quantify-
ing the percentage of DARC+ venular surface area in the
total vascular (CD31+) surface area. In the chosen sam-
ple, the DARC+ fraction was approximately 14% of the
total CD31+ surface area (Additional file 8: Figure S7).
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By comparison, the average frequency of DARC+ V-ECs
among total ECs in adipose tissue was approximately
4%, as detected by flow cytometry (Fig. 4c). This appar-
ent difference must be interpreted with caution for
several reasons. Firstly, in order to obtain a sufficient
number of ECs from adipose tissue for FACS analysis,
we pooled subcutaneous and epididymal fat pads,
which might have a lower venular density. Secondly,
A Adipose tissue
CD31 DARC merge 























Fig. 2 DARC is a robust marker of venular endothelial cell differentiation. a Representative confocal micrographs of whole mount stainings of
adipose tissue (omentum, 20× objective, scale bars = 200 μm, top row) and skin (ear, 10× objective, scale bars = 300 μm, bottom row) with MAbs
against CD31 (green), DARC (red), and LYVE-1 (blue). Arrows in images on the left identify representative arterioles (art.), capillaries (cap.), and
venules (ven.). The boxed area in the merged image of adipose tissue was magnified (far right, top row) to illustrate concentrated DARC staining
at inter-endothelial junctions (arrowhead). Adipose tissue n > 10 experiments, skin n > 10 experiments. b Semi-quantitative analysis of DARC
expression in arterioles (art.), capillaries (cap.), pre-venular capillaries (PVC), post-capillary venules (PCV), and collecting venules (col. ven.) in adipose
tissue. Data represent 16 microvascular trees from seven fields of view of omenta from two mice. Supporting data values are included in
Additional file 2. Representative confocal micrographs of tissues stained with anti-CD31 (green) and anti-DARC (red) depict positive, partial, and
negative DARC staining on PVCs and partial DARC expression on PCVs. Error bars depict mean ± SEM
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Fig. 3 (See legend on next page.)
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in order to obtain sufficient resolution of vascular
structures of interest within whole-mount prepara-
tions, we acquired 3D scans from carefully selected
regions that contained, within the same field of view,
all microvascular structures of interest, i.e., arterioles,
capillary network, and at least one complete venular
tree. This limits the choice of suitable areas and may
have introduced a selection bias that could result in
over-representation of venules. Finally, it is also
possible that ECs in different microvascular segments
may differ in size. For example, if the average luminal
surface area covered per V-EC is greater than that
covered by capillary ECs, the venular surface area
would be fractionally larger than the percentage of V-
ECs. Our current technology does not allow us to
accurately resolve individual ECs in intact tissues, so
we cannot address this issue with certainty.
Interestingly, a topological analysis of the microvascu-
lar anatomy in murine MLNs [37] estimated that HEVs
composed approximately 12% of the overall vascular
length, which is in good agreement with our flow cytom-
etry data showing 14% DARC+ V-ECs among BECs in
MLN.
Consistent with reports of DARC expression in human
skin [38], murine DARC was detectable by FACS on
subsets of LECs in LNs, adipose tissue, and skin (Add-
itional file 9: Figure S8); however, DARC expression on
LECs was too low to be detectable in these tissues by
confocal microscopy (Figs. 1 and 2).
DARC as a pan-venular marker
Next, we asked whether DARC expression correlates
with other known venule-associated markers. For ex-
ample, P- and E-selectin are constitutively expressed (al-
though challenging to detect by immunostaining) in
resting skin venules [30, 39, 40]. Indeed, when mRNA
levels of Darc, Selp, and Sele were measured by qPCR in
sorted dermal DARC+ V-ECs, DARC– NV-ECs, and
LECs, all three mRNA species were detected exclusively
in V-ECs (Fig. 5a).
Similarly, HEVs (unlike other microvessels) in PLN ex-
press carbohydrate sulfotransferase 4 (Chst4) [41] and
fucosyltransferase VII (Fut7) [42], enzymes involved in
the biosynthesis of 6-sulfo-SLeX on core 1 O-glycans
that comprise the PNAd marker [40, 43]. PNAd is also
synthesized by most HEVs in MLN, which additionally
expresses MAdCAM-1 [44, 45]. Accordingly, Darc
mRNA expression in PLN and MLN was restricted to V-
ECs and correlated closely with Chst4 and Fut7 in both
tissues and with Madcam1 in MLNs (Fig. 5b, c). These
observations were confirmed at the protein level by
FACS analysis of PLN and MLN BECs. Of note, while al-
most all PNAd+ and MAdCAM-1+ BECs expressed
DARC, up to approximately 15% of DARC+ ECs were
PNAd– and MAdCAM-1– (Fig. 5d, e). These ECs likely
derived from medullary segments of the venular tree,
which are lined by flat ECs and do not express vascular
addressins [46].
Since PNAd, MAdCAM-1, and the endothelial
selectins are not only restricted to V-ECs, but are also
subject to a strong tissue bias at steady-state [47], we
also stained BECs for ICAM-1, which is constitutively
expressed on ECs throughout the body [48]. Indeed,
BECs expressed ICAM-1 in both skin and LNs,
whereas PNAd and MAdCAM-1 were absent on der-
mal BECs [49] (Fig. 5d–f ). Interestingly, although
ICAM-1 expression was more pronounced and uni-
form in venules than on other ECs, it was also
expressed, albeit at a lower level, on most DARC–
NV-ECs. Thus, when compared to other known venu-
lar surface moieties, DARC stands out as a truly pan-
venular marker that shows exquisite specificity for V-
ECs and is readily detectable by IHS and flow cytom-
etry in every murine tissue analyzed.
Detection of venular DARC expression by IVM
Having determined that our anti-DARC MAb recognizes
surface-expressed DARC in frozen sections and whole
mount preparations of murine tissues ex vivo and on in-
tact transfectants and isolated ECs in vitro, we asked
whether the MAb could pinpoint microvascular DARC
expression in vivo. We transplanted irradiated C57BL/6
mice with DARC–/– BM (Fig. 6a); at 8 weeks after BM
transplantation, this resulted in absent DARC expression
on RBCs. Thus, upon intra-arterial injection of Alexa
Fluor-488 labeled anti-DARC, the MAb remained free to
bind endothelial DARC without being captured by
DARC+ RBCs.
Luminal DARC expression was readily detectable by
epifluorescence IVM [5] in HEVs and large collecting
(See figure on previous page.)
Fig. 3 DARC expression on whole mount and frozen section stainings. Representative confocal micrographs of whole mount staining of (a) cremaster
muscle (20× objective, scale bar = 200 μm), (b) bladder (10× objective, scale bar = 300 μm), and (c) conjunctival vessels (10× objective, scale bar = 300 μm)
with MAbs against CD31 (green) and DARC (red). Representative confocal micrographs of frozen sections from (d) brain (20× objective, scale bar = 200 μm),
(e) Peyer’s patches (10× objective, scale bar = 300 μm), (f) mesenteric lymph nodes (20× objective, scale bar = 200 μm), (g) thymus (10× objective, scale
bar = 300 μm), (h) pancreas (20× objective, scale bar = 200 μm), (i) small intestine (20× objective, scale bar = 100 μm), and (j) colon (10× objective, scale
bar = 300 μm) with MAbs against: CD31 (green), DARC (red), insulin (white), MAdCAM1 (white), or UEA-1 (white) as indicated. L indicates lumen of small
intestine and colon. n = at least three experiments for each tissue
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venules in subiliac LNs (Fig. 6b). Epifluorescence IVM
of intact skull BM [31] identified prominent DARC
expression in intermediate venules, collecting venules,
post-sinusoidal venules, and sinusoids (Fig. 6c). Seg-
mental microvascular immunoreactivity, particularly at
inter-cellular junctions was also readily detected by
IVM in intact ear skin and in surgically exposed cre-
master muscle (Fig. 6d–f ). By contrast, as expected,
none of these IVM models showed detectable DARC
expression in arterioles or capillaries.
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Fig. 4 Identification of DARC+ venular endothelial cells (V-ECs) by flow cytometry. a Gating strategy to identify EC subsets in single cell
suspensions of murine lymph nodes; BEC blood ECs, LEC lymphatic ECs, NV-EC non-venular EC. b Using the same gating strategy as in panel A,
the frequency of DARC+ V-EC and DARC– NV-EV among BECs was assessed in multiple tissues (upper row). The lower row shows the same
samples stained with an isotype-matched control MAb. c Quantitative assessment of the frequency of DARC+ V-ECs among total BECs in a panel
of fresh murine tissues. Error bars depict mean ± SEM of recovered V-EC frequencies among BECs in mesenteric LN (n = 11), peripheral LN (n = 14),
skin (n = 18), adipose tissue (n = 6), colon (n = 10), small intestine (n = 6), brain (n = 5), and pancreas (n = 5). nsP > 0.05, *P ≤ 0.05; **P ≤ 0.01











































Fig. 5 (See legend on next page.)
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DARC+ microvessels uniquely support physiologic
leukocyte adhesion
To independently verify that the DARC+ microvessels
detected by IVM were indeed venules, we made use of
the fact that leukocytes undergo constitutive selectin-
mediated rolling interactions in venules, but not in capil-
laries or arterioles in murine ear skin [30]. Thus, we
injected fluorescent anti-DARC MAb into mice and then
injected fluorescently tagged leukocytes into the carotid
artery to quantify leukocyte rolling fractions in dermal
DARC+ and DARC– microvessels by IVM [30]. All
DARC+ microvessels supported robust rolling interac-
tions, whereas rolling was absent in all DARC– micro-
vessels, indicating that DARC delineates specifically pro-
adhesive venules, but not non-adhesive non-venular
microvessels (Fig. 6 g, Additional file 10: movie 1).
Discussion
Julius Cohnheim first noted that leukocyte recruitment
from blood to inflamed tissues occurs preferentially
within venular segments of the microcirculation [50]. In-
deed, numerous studies have confirmed this fundamen-
tal observation in multiple tissues and a variety of
species [6, 51, 52]. However, this property of venules is
not explained by hemodynamic factors, but a conse-
quence of endothelial specialization [3]. To date, the
molecular ‘wiring diagram’ that enables V-ECs to func-
tion as the principal gatekeepers for leukocyte access to
tissues remains unknown.
Notwithstanding, a handful of venular surface molecules
are known to be restricted to a specific vascular bed. Vascu-
lar addressins, PNAd [34] and MAdCAM-1 [44], in HEVs
support leukocyte recruitment to secondary lymphoid or-
gans. P- and E-selectin mediate leukocyte rolling at steady-
state in skin [49], BM [31, 53], and thymus [54], as well as
other organs during acute inflammation [55, 56]. Venules
may also be distinguished from arterioles by higher vWF
expression, although this difference is subtle and does not
always allow unequivocal determination of microvascular
identity [57]. Indeed, no single marker is known to date to
robustly and unequivocally discriminate between venular
and non-venular endothelium in all (or most) tissues. The
existence of such a marker and an appropriate biological
tool to detect that marker on intact ECs could facilitate fur-
ther studies to uncover the molecular underpinnings of V-
EC and NV-EC phenotype and function.
Here, we explored whether a newly developed anti-
mouse DARC MAb is useful to discriminate and isolate
primary V-ECs and NV-ECs in laboratory mice. Several
studies have suggested that DARC positively and select-
ively identifies V-ECs, at least in some human [13, 14]
and murine tissues [15]. However, a rigorous analysis of
the macro- and microanatomic distribution of DARC
has not been performed, presumably because previously
available reagents did not have sufficient sensitivity and/
or specificity. This is not surprising considering that
DARC is highly conserved among mammals; the nucleo-
tide sequences for mouse (NM_010045.2) and rat
(XM_002728033.3) DARC share an overall identity of
88%. When comparing protein sequences, it must be
noted that DARC is a serpentine receptor with four vari-
ably sized extracellular domains separated by seven
transmembrane domains [58]. For DARC detection on
intact cells, antibodies must recognize extracellular epi-
topes on the native receptor. The ectodomains of DARC
in mouse and rat share 85.2% similarity in the N-
terminal ectodomain and 100%, 65%, and 86.3% identity
in ectodomains 1, 2, and 3, respectively. The overall
extracellular sequence identity in mice and rats is
83.76%, corresponding to 19 amino acids that differ be-
tween the two species to serve as potential epitope(s) for
non-self-reactive antibodies.
Despite this high homology between mouse and rat
DARC, we were able to immunize rats using a stably
transfected rat cell line that over-expressed mouse DARC
as the immunogen. This strategy yielded a MAb that spe-
cifically and selectively recognized DARC on transfectants,
erythroid cells, and microvascular ECs. This reagent
clearly delineated DARC+ venules in lymphoid and non-
lymphoid tissues of different mouse strains in vitro and in
vivo. The MAb was active in multiple applications, includ-
ing immunofluorescence staining of whole mounts and
tissue sections, FACS, western blot, and IVM. After i.v. in-
jection of fluorescent anti-DARC MAb, selective staining
of V-ECs was readily detectable by IVM in four different
tissues. In each setting, circulating leukocytes interacted
(See figure on previous page.)
Fig. 5 Correlation of DARC expression and known venular markers. a RT-qPCR showing DARC (Darc), P- (Selp), and E-selectins (Sele) expression at the
mRNA level in cell-sorted V-EC (CD45-CD31 + gp38-DARC+), NV-EC (CD45-CD31 + gp38-DARC-), and LEC (CD45-CD31 + gp38+) from skin tissue. b RT-
qPCR showing Darc, Carbohydrate sulfotransferase 4 (Chst4), and Fucosyltransferase VII (Fut7) expression at the mRNA level in cell-sorted V-EC, NV-EC,
and LEC from peripheral lymph nodes (PLN; pool of inguinals, brachials, axillaries, cervicals, and auriculars). c RT-qPCR showing Darc, Chst4, Fut7, and
mucosal vascular addressin cell adhesion molecule 1 (Madcam1) expression at the mRNA level in cell-sorted V-EC, NV-EC, and LEC from mesenteric
lymph nodes (MLN). Expression data are shown relative to GAPDH of a pool of three experiments for each gene and expressed in arbitrary units (A.U.).
Error bars depict mean ± SEM. nsP > 0.05, **P≤ 0.01, ***P≤ 0.001. Supporting data values are included in Additional file 2. d–f Flow cytometry contour
plots of DARC and peripheral node addressin (PNAd) expression (d), DARC and MAdCAM-1 expression (e), and DARC and ICAM-1 expression (f) in ear
skin, PLNs, and MLNs. Cell suspensions were gated on CD45-CD31 + gp38-BEC subset for flow cytometry analysis in all the tissues. n = 3 experiments
for each tissue
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exclusively with DARC+ microvessels, indicating that our
MAb positively identifies microvessels capable of support-
ing leukocyte trafficking.
Our analysis of restricted venular DARC expression is
consistent with previous reports that have shown DARC
+ V-ECs in PLNs, MLNs, and brain [15, 17]. In addition,
we report that DARC is also a venule-specific marker in
many other murine tissues that had not been examined
previously, including the skin, BM, adipose tissue, cre-
master muscle, bladder, conjunctival vessels, small intes-
tine, colon, Peyer’s patches, thymus, and pancreas. Of
note, DARC expression has also been reported on Pur-
kinje cells [22]. However, although the polyclonal serum
of the immunized rat stained Purkinje cells in frozen
sections, our anti-mouse DARC MAb failed to do so.
The reason for this differential immunoreactivity is un-
clear, but might reflect differential post-translational
modification(s) of Purkinje cell-expressed DARC at or
near the epitope recognized by the MAb. Consistent
with this idea, our western blot analysis showed a dis-
crepancy between the predicted molecular mass of
mouse DARC (36 kDa) and the apparent molecular
weight (~45 kDa) of cell-derived protein. DARC has
multiple potential sites for post-translational modifica-
tions, such as glycosylation, phosphorylation, and tyro-
sine sulfation, which have been described for other
chemokine receptors. Indeed, human DARC is glycosyl-
ated in positions 16 and 33 [59], but it has not been de-
termined whether DARC may undergo tissue-specific
post-translational modifications.
The fact that our anti-DARC MAb is compatible with
multi-color flow cytometry to discriminate between differ-
ent subsets of primary microvascular ECs allowed us to
compare the composition of vascular beds from different
tissues. Our analysis suggests that the skin and LNs contain
a larger fraction of DARC+ V-ECs than most other tissues,
which could potentially reflect the fact that these organs
undergo particularly vigorous immunosurveillance and are
frequent staging grounds for immune responses against in-
vading pathogens, requiring a large vascular surface area
capable of supporting leukocyte trafficking. However, it
should be cautioned that the recovery of intact EC subsets
from tissue preparations is likely incomplete and may not
necessarily reflect the true abundance of ECs in situ. More-
over, we observed that the epitope recognized by our MAb
is sensitive to proteolytic degradation during tissue diges-
tion. Thus, to achieve reliable yields of DARC+ V-ECs and
DARC– NV-ECs, it was necessary to develop customized
isolation protocols for each tissue, which could potentially
impact the apparent abundance of V-ECs in any given
tissue.
Erythrocyte-expressed DARC binds inflammatory che-
mokines and, in doing so, RBCs serve as a sink or reser-
voir modulating circulating chemokine abundance and
pharmacokinetics [25, 60]. DARC expression during
murine and human erythroid development has been previ-
ously examined only at the mRNA level [36] and by west-
ern blot of in vitro cultured erythroblasts [35]. In contrast
to these analytical methods, although DARC was readily
detectable on RBCs in peripheral blood, DARC expression
is even more pronounced on BM-resident erythroid pro-
genitors [61]. Thus, it will be important to investigate the
role of erythroid and endothelial DARC in BM during
hematopoiesis. In addition, DARC was detectable in BM si-
nusoidal ECs but was absent from BM-resident myeloid
cells. These results differ from a recent study that reported
that a polyclonal anti-DARC Ab stained a subset of macro-
phages, but not ECs, in single-cell suspensions of murine
BM [24]. These contrasting observations remain to be fully
explained, but could potentially reflect differential reactivity
of the immunoreagents used or distinct DARC epitope
availability on specific host cell types, or unrecognized loss
of DARC epitope(s) during tissue preparation, or any com-
bination of these factors.
The physiological role of DARC is rooted in its capacity
to bind a variety of inflammatory chemokines [10, 11]. Sev-
eral DARC ‘knockout’ mouse strains have been generated
whose phenotype indicates a regulatory role for DARC on
ECs and RBCs during inflammatory processes [25, 62, 63].
When inflammatory chemokines are generated in the
(See figure on previous page.)
Fig. 6 Intravital microscopy (IVM) of leukocyte adhesion in DARC+ venules. a Schematic representation of IVM experiment. b Alexa Fluor 488 labeled anti-
mouse DARC MAb staining of microvessels in subiliac lymph node. Branching order designation of intranodal venular segments was performed as in ref.
[5]. Left: micrograph at the LN hilus showing a large DARC+ CV (order I) that drains venous blood into a DARC– extra-lymphoid vein (ELV); 20× objective.
Right: Representative intranodal venular tree with branching orders identified in Roman numerals. c DARC expression in BM intermediate venules (IV),
collecting venules (CV), post-sinusoids venules (PSV), and sinusoids (s). Microvascular segment designation was as in [31]; 10× objective (n = 3 experiments).
d Intravital fluorescent micrographs of murine ear skin after injection of fluorescent leukocytes. Images were taken during an initial control period (left), after
injection of Alexa Fluor 488 labeled anti-mouse DARC MAb (middle) and after subsequent injection of FITC-dextran, which delineates the intravascular
compartment in all microvessels. Leukocytes rolling in DARC+ venules are identified by arrowheads. Arteriole (art.), venule (ven.); 20× objective (n = 3
experiments). See Additional file 10: movie 1. e Leukocyte rolling in DARC+ venules in cremaster muscle; 10× objective. Arrowhead in left panel indicates a
non-adherent leukocyte captured while passing through an arteriole. See Additional file 11: movie 2. f Dashed arrowhead indicates pronounced DARC
expression at the junction between adjacent ECs in cremaster muscle; 40× objective. g Rolling fractions (percent of rolling cells in the total flux of cells
passing a microvessel) of calcein-labeled neutrophils in ear skin microvessels was assessed; n = 3 mice, data points from same animal are highlighted in
same color (black, red or green). Error bars show mean ± SEM. ***P< 0.001. Supporting data values for this analysis are included in Additional file 2
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extravascular space, they bind DARC on the basolateral side
of V-ECs and the complex is then transcytosed across the
caveoli network to the luminal surface for presentation to
passing leukocytes [12]. The tight restriction of DARC ex-
pression to small venules focusses chemokine bioavailability
to postcapillary microvessels and hence is likely to contrib-
ute to the strong bias of leukocyte migration in venular seg-
ments. Of note, immunofluorescence staining of whole-
mount tissues suggests that DARC is concentrated at inter-
cellular junctions between V-ECs, similar to other leukocyte
traffic molecules such as CD31 [64, 65], ICAM-2 [66, 67],
and CXCR7 [68]. The physiological significance of this ob-
servation remains undetermined.
Interestingly, although DARC expression was uniform
and prominent in PCVs and in small to mid-size CVs in
every murine tissue examined, it was absent in larger CVs
and veins, indicating that DARC is not merely a marker of
ECs exposed to deoxygenated blood. In fact, the environ-
mental signal(s) that regulate(s) microvascular DARC ex-
pression remain(s) to be identified. It is also not clear
whether all ECs that interact with blood-borne leukocytes
inevitably express DARC. In fact, our results suggest that
this is unlikely since atherosclerotic plaques in aortas of
Apoe–/– mice did not display luminal DARC. However,
DARC+ microvessels were readily identified within the aortic
wall in C57BL/6 mice, and DARC+ vasa vasorum were even
more prominent in aortas of Apoe–/– mice. Thus, a network
of microvessels that include bona fide venules supplies large
arteries prone to atherosclerosis in mice. Whether and to
what extent these vessels can contribute to the recruitment
of atherogenic leukocytes remains to be determined.
Conclusion
In summary, we report the generation and extensive
characterization of a MAb against mouse DARC/ACKR1/
CD234. Using this new biological tool, we demonstrate that
DARC is truly a pan-venular marker. This MAb will be
useful for future studies on the cellular and molecular un-
derpinnings of segmental endothelial specialization in the
peripheral microvasculature.
Additional files
Additional file 1: Figure S1. Generation of monoclonal anti-mouse
DARC antibody. To generate the monoclonal anti-mouse DARC antibody,
rats were immunized with a stably transfected PC-12 rat cell line express-
ing DARC-eGFP fusion protein. (A) Validation of membrane expression
was performed by confocal microscopy using HEK-293 cells stably trans-
fected to express DARC-eGFP. (B) Before immunization, DARC-eGFP PC-12
cells were treated with sodium butyrate to maximize the expression of
the transfected fusion protein. Flow cytometry histogram shows eGFP
fluorescence intensity on PC-12 cells before (grey) and after 24 hours of
sodium butyrate treatment (black). (C) Adult rats were immunized four
times at 2-week intervals with 5 × 106 sodium butyrate conditioned
DARC-eGFP PC-12 transfectants. The first immunization was performed
with Complete Freund Adjuvant via s.c. and i.p. routes, the second
injection was performed with Incomplete Freund Adjuvant i.p., and the
third and last injections were each administered i.p. without adjuvant. (D)
Immune sera were screened by flow cytometry for reactivity with DARC
ectodomains using HEK-293 cells expressing DARC-eGFP fusion protein.
Fluorescence intensity is expressed as geometric mean of fluorescence
(GeoMFI). Following splenocyte fusion, twelve 96-well plates were screened
by flow cytometry, only two wells showed reactivity against mouse DARC.
One clone producing an anti-mouse DARC MAb was isolated, expanded,
subcloned, purified, and labeled for this study. (PDF 190 kb)
Additional file 2: Raw data for Fig 2b, Fig 5, Fig 6g, Additional file 7:
Figure S6B and Additional file 8: Figure S7. (XLS 217 kb)
Additional file 3: Figure S2. Anti-mouse DARC MAb cross-reactivity and
function. (A) Representative flow cytometry histograms of TER-119+ RBCs and
CD45+ hematopoietic cells stained with anti-mouse DARC MAb (black) and
isotype control (grey) from C57BL/6 and BALB/c mice (n = 6 mice per group).
(B) Representative flow cytometry histograms of mouse, rat, and human RBCs
stained with anti-mouse DARC MAb (black) and isotype control (grey). The
anti-mouse DARC MAb does not show specific reactivity for the rat and
human erythrocyte form of DARC protein (n = 2 individuals per group), (C)
Blood was taken from Duffy-positive laboratory donors and 106 red cells were
incubated with increasing concentrations of CXCL8 and mCXCL1 in 100 μL PBS
with 0.5% BSA for 1 h at 37 °C and subsequently 1 μL of anti-human Fy6 for
30 min, and finally 1 μL of PE-conjugated goat anti-mouse antibody added.
For determination of inhibition of directly conjugated anti-murine DARC
antibody binding by chemokines, blood was taken from wildtype mice and
106 red cells were incubated with increasing concentrations of CXCL8 and
mCXCL1 in 100 μL PBS with 0.5% BSA for 1 h at 37 °C and subsequently
1 μL of Alexa-647 conjugated anti-murine DARC for 30 min. Mean
fluorescence of DARC MAb stainings were measured by flow cytometry.
(PDF 218 kb)
Additional file 4: Figure S3. Quantification of DARC expression on blood
microvasculature. To determine DARC expression on arterioles, capillaries,
pre-venular capillaries (PVC), post-capillary venules (PCV), and collecting venules,
we analyzed DARC expression in a microvascular network stained with
anti-CD31 (green) and anti-DARC (red). White squares indicate the regions
selected to illustrate positive, partial, or negative pre-venular capillaries (PVC) for
DARC expression as well as partial DARC expression on post-capillary venules
(PCV) in Fig. 2; 20× objective, scale bars = 200 μm. (PDF 391 kb)
Additional file 5: Figure S4. DARC expression on vein and artery.
Representative confocal micrographs of whole mount staining of femoral
vessels stained with anti-DARC or isotype control (red), anti-CD31 (green),
and DAPI (blue) as indicated. Bright field indicates the localization of vein
and artery. DARC is not detected on vein and artery but is expressed on
venules (arrowhead) in the microvasculature of the surrounding connective
tissue; 10× objective, scale bars = 300 μm (n = 3 experiments). (PDF 731 kb)
Additional file 6: Figure S5. DARC positive vessels in vasa vasorum of
aorta of wildtype (WT) and Apoe–/– mice. Representative confocal micrographs
of DARC expression on venules in the vasa vasorum of aorta of WT (A) or
Apoe–/– mice (B). Tissues were stained with anti-CD31 (green), anti-DARC MAb
(red), and Yoyo-1 (blue) was used to stain nuclei. Arrows indicate DARC+
vessels and arrowheads indicate DARC– vessels (WT n = 5 experiments, Apoe–/
– n = 8 experiments). (PDF 426 kb)
Additional file 7: Figure S6. DARC epitope sensitivity to enzymatic
digestion. (A) Representative flow cytometry histograms of DARC expression on
RBCs. RBCs from blood were digested at 37 °C with different concentration of
enzymes as indicated: Collagenase VII (1×) = 86 μg/mL, Collagenase D (1×) =
2.5 mg/mL and Collagenase II (1×) = 1.5 mg/mL. RBCs at 4 °C and 37 °C
without digestion are used as positive controls for DARC expression. Flow
cytometry was performed to detect DARC expression (n = 5 experiments).
(B) Quantification of DARC expression on RBCs, results are shown as delta
Geometric Mean Intensity of Fluorescence (n = 3 mice/group). Error bars show
mean ± SEM. nsP> 0.05, **P≤ 0.01, ***P≤ 0.001. Supporting data values are
included in Additional file 2. (PDF 180 kb)
Additional file 8: Figure S7. DARC expression in whole mount adipose
tissue. Confocal micrographs of whole mount staining of adipose tissue
(omentum) were analyzed for CD31 (green) and DARC (red) expression.
The fluorescence intensity images (upper panels) and the corresponding
3D rendering images (lower panels) are shown. Surface area for CD31
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and DARC channels were calculated using Imaris software and shown as
μm2. 10× objective, scale bars = 100 μm. Supporting data values are
included in Additional file 2. (PDF 261 kb)
Additional file 9: Figure S8. DARC expression on lymphatic endothelial
cells. (A) Flow cytometry analysis of DARC expression on lymphatic
endothelial cells (LECs) in mesenteric lymph node (MLN), peripheral
lymph node (PLN), adipose tissue, and skin. Live LECs are defined as
followed: CD45 negative, CD31 and gp38 positive. DARC expression is
shown as frequency of LEC subset. (B) Bar graph showing the frequency of
DARC+ LECs among total LEC population in MLN (n = 7), PLN (n = 6), adipose
tissue (AT) (n = 6), and skin (n = 6). Data were excluded from the analysis if
number of events in LEC gate was less than 500. Error bars show mean± SEM.
*P≤ 0.05, ***P≤ 0.001. (C) DARC expression shown as geometric mean of
intensity of fluorescence (Geo.MFI) on venules (V-EC), lymphatic EC (LEC), and
non-venules (NV-EC). Error bars show mean± SEM. nsP> 0.05, **P≤ 0.01, ***P≤
0.001. “#” Identical statistic results for skin, MLN, and PLN. Statistic results for AT
are indicated in blue. (PDF 186 kb)
Additional file 10: movie 1. DARC+ microvessels uniquely support
physiological leukocyte adhesion in skin. DARC–/– bone marrow chimeric mice
were anaesthetized and ear skin was positioned on a custom-built stage for
epifluorescence intravital microscopy. BM neutrophils were enriched using a
60–72% Percoll gradient and labeled with calcein AM (5 μM) prior to injection
through a catheter in the carotid artery. Subsequently, Alexa Fluor 488 anti-
DARC MAb (50–100 μg/mouse) was injected and cell behavior in venules was
recorded under stroboscopic epi-illumination in 10 min recordings through
20× water-immersion objectives. Injection of FITC-Dextran (2 mDa) delineates
the intravascular compartment in all microvessels. All DARC+ microvessels sup-
ported robust rolling interactions, whereas rolling was absent in all DARC–
microvessels, indicating that DARC delineates specifically pro-adhesive venules,
but not non-adhesive non-venular microvessels. (MOV 9903 kb)
Additional file 11: movie 2. DARC+ microvessels uniquely support
physiological leukocyte adhesion in cremaster muscle. DARC–/– bone
marrow chimeric mice were anaesthetized and cremaster muscle was
positioned on a custom-built stage for epifluorescence intravital micros-
copy. BM neutrophils were enriched using a 60–72% Percoll gradient and
labeled with calcein AM (5 μM) prior to injection through a catheter in a
femoral artery feeding the tissue. Subsequently, Alexa Fluor 488 anti-
DARC MAb (50–100 μg/mouse) was injected and cell behavior in venules
was recorded under stroboscopic epi-illumination in 10 min recordings
through 10× water-immersion objectives. Injection of FITC-Dextran (2
mDa) delineates the intravascular compartment in all microvessels. All
DARC+ microvessels supported robust rolling interactions, whereas rolling
was absent in all DARC– microvessels, indicating that DARC delineates
specifically pro-adhesive venules, but not non-adhesive non-venular
microvessels. (MOV 16573 kb)
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